Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.

Previous Day
Next Day

Google Calendar
iCalendar
Outlook 365
Outlook Live
Export .ics file
Export Outlook .ics file

Startpage
Calendar
Day

About Alligator

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

Privacy Policy | Use of Cookies | Change your cookie settings here.
Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.

Settings Accept all

Cookies

Do your settings below. Or read our cookie policy.

Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
Marketing
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.

Save Accept all